Ocular Surface Squamous Neoplasia: A Cohort Study and Updates in the Pathogenesis, Diagnosis, and Medical Management

Topical agents are effective and well-tolerated treatments for OSSN, with IFNα-2b demonstrating faster response times in this cohort. The literature highlights a lack of prospective randomized trials comparing these therapies. Furthermore, limited understanding of the molecular mechanisms underlying OSSN pathogenesis continues to hinder individualized treatment strategies and risk stratification.